var data={"title":"Budesonide and formoterol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Budesonide and formoterol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5764?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=budesonide-and-formoterol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Budesonide and formoterol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=budesonide-and-formoterol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Budesonide and formoterol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50875985\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Long-acting Beta Agonists/Inhaled Corticosteroids Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has issued a safety alert announcing that, after a review of 4 large clinical trials, treating asthma with a long-acting beta agonist (LABA) in combination with an inhaled corticosteroid (ICS) does not significantly increase serious asthma-related adverse events (asthma-related hospitalizations, need for intubation, or asthma-related deaths) compared to treatment with an ICS alone. In light of these results, the Boxed Warning regarding asthma-related death has been removed from labels of medications containing <i>both</i> an ICS and LABA. Using LABAs without an ICS is associated with an increased risk of asthma-related death; therefore, the Boxed Warnings stating this will remain on labels of all single-ingredient LABA medications.</p>\n        <p style=\"text-indent:0em;\">Healthcare professionals should refer to the most recently approved drug labels for recommendations on using ICS in combination with LABAs. More information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20update%20on%20long-acting%20beta%20agonists%20%28LABAs%29&utm_medium=email&utm_source=Eloqua&amp;token=uo6A9PtUuxWTi4lTE1XNtjZu152WbjMmM807MNFrj/Kg9w2hCrpIoQGgaZO2k23UxW6LecSmEMdKnk21J2TjFGwWde2STooICelklcCGZQb7LJ1ygFuSQvuqFeq+AG1pCrYE7hG+Alb2CaHavRr9IeVqSKmkJT80OO4eqnphQgpSqmG5mBZcKQ3px9yOD1qb8kX4nE7W4r3CCw87KPSyeprfh5O+wjqomRxtEgWubXU=&amp;TOPIC_ID=8524\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20update%20on%20long-acting%20beta%20agonists%20%28LABAs%29&amp;utm_medium=email&amp;utm_source=Eloqua</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3071871\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Symbicort</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142769\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Symbicort</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142784\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Beta<sub>2</sub> Agonist;</li>\n      <li>\n        Beta<sub>2</sub>-Adrenergic Agonist, Long-Acting;</li>\n      <li>\n        Corticosteroid, Inhalant (Oral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142772\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If asthma or COPD symptoms occur in the period between doses, an inhaled, short-acting beta<sub>2</sub>-agonist should be taken for immediate relief.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Starting dose is based on asthma severity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Budesonide 80 mcg/formoterol 4.5 mcg or budesonide 160 mcg/formoterol 4.5 mcg: Metered-dose inhaler: 2 inhalations twice daily; if response is inadequate, may increase to higher dose combination after 1 to 2 weeks (maximum: budesonide 160 mcg/formoterol 4.5 mcg: 2 inhalations twice daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 100 Turbuhaler, Symbicort 200 Turbuhaler [Canadian products]: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 1 to 2 inhalations twice daily until symptom control, then titrate to lowest effective dosage to maintain control</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 1 to 2 inhalations once or twice daily (maximum: 8 inhalations/day as temporary treatment in periods of worsening asthma)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort Maintenance and Reliever Therapy (Symbicort SMART) [Canadian product]: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance:</i> Symbicort 100 Turbuhaler or Symbicort 200 Turbuhaler: 1 to 2 inhalations twice daily <b>or </b>2 inhalations once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Reliever therapy:</i> Symbicort 100 Turbuhaler or Symbicort 200 Turbuhaler: 1 additional inhalation as needed, may repeat if no relief for up to 6 inhalations total (maximum: 8 inhalations/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>COPD:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Budesonide 160 mcg/formoterol 4.5 mcg: Metered dose inhaler: 2 inhalations twice daily (maximum: 2 inhalations twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 200 Turbuhaler [Canadian product]: Dry powder inhaler: 2 inhalations twice daily (maximum: 2 inhalations twice daily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142779\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=budesonide-and-formoterol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Budesonide and formoterol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Asthma:</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If asthma symptoms occur in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 6 to 11 years: Budesonide 80 mcg/formoterol 4.5 mcg: Metered dose inhaler: 2 inhalations twice daily (maximum: 2 inhalations twice daily). <b>Note:</b> The guidelines recommend use in children 5 to 11 years (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062966\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682318\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7310404\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution and monitor closely; may lead to accumulation of budesonide and formoterol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142757\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 80/4.5: Budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6.9 g); budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 160/4.5: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6 g); budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46518223\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Symbicort 6.9 g canisters contain 60 actuations, and the 10.2 g canisters contain 120 actuations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950028\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 100 Turbuhaler: Budesonide 100 mcg and formoterol dihydrate 6 mcg per inhalation (available in 60 or 120 metered doses) [delivers ~80 mcg budesonide and 4.5 mcg formoterol per inhalation; contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symbicort 200 Turbuhaler: Budesonide 200 mcg and formoterol dihydrate 6 mcg per inhalation (available in 60 or 120 metered doses) [delivers ~160 mcg budesonide and 4.5 mcg formoterol per inhalation; contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874387\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s013lbl.pdf#page=45&amp;token=xQJV5Tov+soBfbZnrE0L3wPi3lQYrFv1Asib51j3RVrBEfAGOQmHDtSIEupk3NDyOgFm3PUlmrMMObSpC7kwQJZPXjhFAkocq4CKXD2u9toAwDHvjn+6WSo70MQxixhp&amp;TOPIC_ID=8524\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s013lbl.pdf#page=45</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142759\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered-dose inhaler: For oral inhalation only administered every morning and evening, approximately 12 hours apart. Prior to first use, inhaler must be primed by releasing 2 test sprays into the air; shake well for 5 seconds before each spray. Inhaler must be reprimed if not used for &gt;7 days or if it has been dropped. Shake well for 5 seconds before each use. Discard inhaler after the labeled number of inhalations have been used or within 3 months after removal from foil pouch. Rinse mouth with water (spit out without swallowing) after each use. Do not wash inhaler with water; clean mouthpiece using a dry wipe every 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply, press the top counter, and hold breath for up to 10 seconds or as long as they comfortably can. Remove mouthpiece from mouth prior to exhalation. Patient should not breathe out through the mouthpiece. Wait &ge;30 seconds prior to the second inhalation dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dry powder inhaler: Symbicort Turbuhaler [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">To &ldquo;load&rdquo; inhaler: Turn red grip on inhaler as far as it will move in one direction, then turn in opposite direction as far as it will go (inhaler is &ldquo;loaded&rdquo; with a dose, indicated by a &ldquo;click&rdquo;). Prior to first use, this procedure should be done twice, it does not need to be repeated with subsequent uses even when not used regularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply and hold breath for as long as they comfortably can. Remove mouthpiece prior to exhalation. Patient should not breathe out through the mouthpiece. Dose is lost if patient drops, shakes, or exhales into inhaler after a dose has been loaded. After use of the inhaler, patient should rinse mouth/oropharynx with water and spit out rinse solution. Do not wash inhaler with water; clean mouthpiece using a dry wipe every 7 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142758\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Treatment of asthma in patients &ge;6 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic obstructive pulmonary disease</b>: Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema; to reduce COPD exacerbations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Budesonide/formoterol is not indicated for the relief of acute bronchospasm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142749\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reported incidences are for adolescents and adults unless specified otherwise. Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7% to 11%; children: &ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (7% to 11%), upper respiratory tract infection (4% to 11%; children: &ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress (1% to 7%), oral candidiasis (1% to 6%), vomiting (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngolaryngeal pain (6% to 9%), pulmonary infection (7% to 8%), lower respiratory tract infection (3% to 8%), sinusitis (4% to 6%), bronchitis (5%), nasal congestion (3%), pharyngitis (children: &ge;3%), rhinitis (children: &ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agitation, anaphylaxis, angina pectoris, angioedema, atrial arrhythmia, behavioral changes, bronchospasm, bruise, cataract, cough, decreased linear skeletal growth rate (pediatric patients), depression, dermatitis, dizziness, extrasystoles, glaucoma, hypercorticoidism signs and symptoms, hyperglycemia, hypersensitivity reaction, hypertension, hypokalemia, hypotension, immunosuppression, increased intraocular pressure, insomnia, muscle cramps, nausea, nervousness, palpitations, pruritus, restlessness, skin rash, tachycardia, throat irritation, tremor, urticaria, ventricular arrhythmia, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142762\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to budesonide, formoterol, or any component of the formulation; primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids and/or sympathomimetics are limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to inhaled lactose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142747\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients from oral corticosteroid therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma-related deaths: The use of long-acting beta-2 agonists (LABAs) as monotherapy is associated with an increased risk of asthma-related deaths. In a large, randomized, placebo-controlled US trial, salmeterol was associated with an increase in asthma-related deaths (SMART 2006); risk is considered a class effect of LABA monotherapy. Additional data from other clinical trials suggest LABA monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. However, data from large randomized, double-blind, active-controlled trials do not show a significant increase in the risk of serious asthma-related events (including hospitalizations, intubations, and death) in adult, adolescent, and pediatric (aged 4 to 11 years) patients when fixed-dose LABAs are used with inhaled corticosteroids combined in a single inhaler compared with inhaled corticosteroid monotherapy. In addition, patients receiving fluticasone/salmeterol had fewer severe asthma exacerbations compared with patients receiving fluticasone alone (Peters 2016; Stempel 2016a; Stempel 2016b). Current guidelines recommend the use of an inhaled corticosteroid before adding a LABA (GINA 2015; NIH/NHLBI 2007). Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone density: Long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density. Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); high doses and/or long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent tuberculosis infections of the respiratory tract; or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin or pooled intravenous immunoglobulin may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. If exposure to measles, prophylaxis with pooled intramuscular immunoglobulin may be indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower respiratory infections: Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while either continuing or interrupting (if necessary) budesonide/formoterol therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Appropriate use: Do <b>not</b> use for acute bronchospasm. Short-acting beta-2 agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do not initiate in patients with significantly worsening or acutely deteriorating asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, or hypertension); beta agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta-2 agonists may also increase risk of arrhythmias and ECG changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; COPD: Appropriate use: Do <b>not</b> use for acute episodes of COPD. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate preexisting diabetes mellitus and ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may lead to accumulation of budesonide and formoterol; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may decrease serum potassium (transient).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use of inhaled corticosteroids. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with seizure disorders; beta agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult Drug Interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of systemic corticosteroids: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142780\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142751\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8524&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: May enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of Formoterol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Budesonide (Oral Inhalation). Management: Concomitant use of these agents is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits. If combined, monitor patients closely for signs and symptoms of corticosteroid excess/toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3071872\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies using this combination. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472558\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if formoterol is present in breast milk; budesonide is present in small amounts. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142754\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">FEV<sub>1</sub>, peak flow meter and/or other pulmonary function tests; monitor growth in pediatric patients, symptom relief, monitor for increased use if short-acting beta<sub>2</sub>-adrenergic agonists (may be a sign of asthma or COPD deterioration); HPA axis suppression; bone mineral density; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142746\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Relaxes bronchial smooth muscle by selective action on beta<sub>2</sub> receptors with little effect on heart rate; formoterol has a long-acting effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide: A corticosteroid which controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes/fibroblasts, and reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142761\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Asthma: 15 minutes; maximum benefit: may take &ge;2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5551127\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Symbicort Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80-4.5 mcg/ACT (6.9 g): $231.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160-4.5 mcg/ACT (6 g): $266.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142765\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alenia (LI);</li>\n      <li>BiResp Spiromax (ES, IE);</li>\n      <li>Budefort (BD);</li>\n      <li>Combiwave FB 200 (MY);</li>\n      <li>Duoresp (IE);</li>\n      <li>DuoResp Spiromax (ES, GB, MT);</li>\n      <li>Foracort (LK, MY);</li>\n      <li>Formohale (LK);</li>\n      <li>Oxycort (BD);</li>\n      <li>Symbicort (HR, IS, LK, LT, LU, LV, SI, SK);</li>\n      <li>Symbicort Forte (TH);</li>\n      <li>Symbicort Rapihaler (AU, SG);</li>\n      <li>Symbicort Turbohaler (BE, DE, GB, IE);</li>\n      <li>Symbicort Turbuhaler (AE, AR, AT, AU, BB, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DK, DO, EE, ET, FI, FR, GR, GT, GY, HK, HN, ID, IL, IT, JM, JO, JP, KR, KW, LB, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, RU, SA, SE, SG, SR, SV, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Symbiocort Turbuhaler (ES, MX);</li>\n      <li>Symbion (BD);</li>\n      <li>Synbicort (RO);</li>\n      <li>Synbicort Turbuhaler (MT, QA);</li>\n      <li>Vannair (BR, CL, HK, NZ, PE);</li>\n      <li>Vent FB Inhaler (IN);</li>\n      <li>Vylaer (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2015. www.ginasthma.org. Updated 2015. Accessed June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, &quot;Guidelines for the Diagnosis and Management of Asthma,&quot; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-and-formoterol-drug-information/abstract-text/16424409/pubmed\" target=\"_blank\" id=\"16424409\">16424409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. <i>N Engl J Med.</i> 2016;375(9):850-860. doi: 10.1056/NEJMoa1511190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-and-formoterol-drug-information/abstract-text/27579635/pubmed\" target=\"_blank\" id=\"27579635\">27579635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rennard SI, Tashkin DP, McElhattan J, et al, &ldquo;Long-Term Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [poster],&rdquo; <i>Chest</i>, 2008, 134:103001S.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rennard SI, Tashkin DP, McElhatta J, et al, &ldquo;Long-Term Tolerability of Budesonide and Formoterol Administered in One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,&rdquo; <i>Chest</i>, 2008, 134:103003S.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Raphiou IH, Kral KM, et al; AUSTRI Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. <i>N Engl J Med</i>. 2016a;374(19):1822-1830. doi: 10.1056/NEJMoa1511049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-and-formoterol-drug-information/abstract-text/26949137/pubmed\" target=\"_blank\" id=\"26949137\">26949137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Szefler SJ, Pedersen S, et al; VESTRI Investigators. Safety of adding salmeterol to fluticasone propionate in children with asthma. <i>N Engl J Med.</i> 2016b;375(9):840-849. doi: 10.1056/NEJMoa1606356.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/budesonide-and-formoterol-drug-information/abstract-text/27579634/pubmed\" target=\"_blank\" id=\"27579634\">27579634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symbicort (budesonide/formoterol) [prescribing information]. Wilmington, DE: AstraZeneca LP; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symbicort Turbuhaler (budesonide/formoterol) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tashkin DP, Rennard SI, Martin P, et al, &ldquo;Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler Over 6 Months in Patients With Chronic Obstructive Pulmonary Disease,&rdquo; <i>Chest</i>, 2008, 134:105001S.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8524 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50875985\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3071871\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F142769\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F142784\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F142772\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F142779\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062966\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682318\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7310404\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142757\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46518223\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950028\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874387\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F142759\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F142758\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142749\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142762\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142747\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F142780\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142751\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3071872\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20472558\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F142754\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142746\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F142761\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5551127\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F142765\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8524|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=budesonide-and-formoterol-patient-drug-information\" class=\"drug drug_patient\">Budesonide and formoterol: Patient drug information</a></li><li><a href=\"topic.htm?path=budesonide-and-formoterol-pediatric-drug-information\" class=\"drug drug_pediatric\">Budesonide and formoterol: Pediatric drug information</a></li></ul></div></div>","javascript":null}